IL265208A - Mast cell stabilizers for treatment of hypercytokinemia and viral infection - Google Patents

Mast cell stabilizers for treatment of hypercytokinemia and viral infection

Info

Publication number
IL265208A
IL265208A IL265208A IL26520819A IL265208A IL 265208 A IL265208 A IL 265208A IL 265208 A IL265208 A IL 265208A IL 26520819 A IL26520819 A IL 26520819A IL 265208 A IL265208 A IL 265208A
Authority
IL
Israel
Prior art keywords
hypercytokinemia
treatment
viral infection
mast stabilizer
cell mast
Prior art date
Application number
IL265208A
Other languages
English (en)
Hebrew (he)
Original Assignee
Emergo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergo Therapeutics Inc filed Critical Emergo Therapeutics Inc
Publication of IL265208A publication Critical patent/IL265208A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
IL265208A 2016-09-08 2019-03-07 Mast cell stabilizers for treatment of hypercytokinemia and viral infection IL265208A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662385021P 2016-09-08 2016-09-08
PCT/US2017/050409 WO2018048989A1 (en) 2016-09-08 2017-09-07 Mast cell stabilizers for treatment of hypercytokinemia and viral infection

Publications (1)

Publication Number Publication Date
IL265208A true IL265208A (en) 2019-05-30

Family

ID=61281984

Family Applications (1)

Application Number Title Priority Date Filing Date
IL265208A IL265208A (en) 2016-09-08 2019-03-07 Mast cell stabilizers for treatment of hypercytokinemia and viral infection

Country Status (15)

Country Link
US (5) US10501527B2 (enExample)
EP (1) EP3509596B1 (enExample)
JP (1) JP2019529541A (enExample)
KR (1) KR20190073365A (enExample)
CN (1) CN109952101A (enExample)
AU (2) AU2017325010A1 (enExample)
BR (1) BR112019004496A2 (enExample)
CA (1) CA3036230A1 (enExample)
ES (1) ES2988617T3 (enExample)
IL (1) IL265208A (enExample)
MX (1) MX389999B (enExample)
MY (1) MY204310A (enExample)
PH (1) PH12019500513A1 (enExample)
RU (1) RU2760682C2 (enExample)
WO (1) WO2018048989A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US20190240194A1 (en) 2016-08-31 2019-08-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
MY204310A (en) * 2016-09-08 2024-08-22 Emergo Therapeutics Inc Mast cell stabilizers for treatment of hypercytokinemia and viral infection
US11478463B2 (en) 2016-10-18 2022-10-25 Emergo Therapeutics, Inc. Mast cell stabilizers for treatment of chronic inflammatory conditions
JP2021535181A (ja) * 2018-09-05 2021-12-16 ザ ジェネラル ホスピタル コーポレイション サイトカイン放出症候群を処置する方法
US12383528B2 (en) 2018-12-10 2025-08-12 The General Hospital Corporation Cromolyn esters and uses thereof
US20200268734A1 (en) * 2019-02-22 2020-08-27 Bridge Pharma, Inc. Methods of treatment of respiratory disorders
US10959992B2 (en) 2019-02-22 2021-03-30 Bridge Pharma Inc. Methods of treatment of asthma and COPD
WO2021178395A1 (en) * 2020-03-06 2021-09-10 Figene, Llc Fibroblast and tlr activated fibroblast treatment of viral induced acute respiratory distress syndrome
WO2021207060A1 (en) * 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
US12612391B2 (en) 2020-12-28 2026-04-28 The General Hospital Corporation Cromolyn derivatives and uses thereof
US20230000852A1 (en) * 2021-06-29 2023-01-05 Bridge Pharma, Inc. Treatment of Dermal Cytokine Storm Syndromes

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878715B1 (en) 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
WO1998035677A1 (en) 1997-02-18 1998-08-20 Bridge Pharma, Inc. Non-sedating histamine antagonist compounds, compositions and methods of use thereof
PL336007A1 (en) 1997-04-03 2000-06-05 Bridge Pharma Chemical compounds of benzocycloheptathiophene
US6207684B1 (en) * 1997-06-09 2001-03-27 Bridge Pharma, Inc. Compounds with combined antihistaminic and mast cell stabilizing activities, intended for ophthalmic use
CA2283603A1 (en) 1998-10-01 2000-04-01 Paul W. Behnke Forced closed-loop cooling for a submersible pump motor
PL353586A1 (en) * 1999-09-13 2003-12-01 Bridge Pharma, Inc.Bridge Pharma, Inc. Optically active isomers of ketotifen and therapeutically active metabolites thereof
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US20050249735A1 (en) 2000-08-07 2005-11-10 Centocor, Inc. Methods of treating ankylosing spondylitis using anti-TNF antibodies and peptides of human tumor necrosis factor
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
WO2003006030A1 (en) * 2001-07-11 2003-01-23 Smith C Steven Novel composition and method for altering allergenic protein in the environment
US6680299B2 (en) 2001-07-27 2004-01-20 Enanta Pharmaceuticals, Inc. 4'-substituted leucomycins
US20060084695A1 (en) 2004-04-29 2006-04-20 John Griffin Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20080311122A1 (en) 2005-11-28 2008-12-18 Medimmune, Llc Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof
WO2008042454A1 (en) 2006-09-29 2008-04-10 Johnson & Johnson Vision Care, Inc. Methods and ophthalmic devices used in the treatment of ocular allergies
US20080139531A1 (en) 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
WO2008153761A1 (en) * 2007-05-23 2008-12-18 Mastcell Pharmaceuticals, Inc. Methods
CA2700818C (en) 2007-10-15 2015-08-11 Revolymer Limited Solvent-free synthesis of amphiphilic polymeric material
WO2009079853A1 (en) 2007-12-24 2009-07-02 Zte Corporation The method and device for protecting the shared channel in the optical transmission system
CN101990437A (zh) * 2008-01-04 2011-03-23 阿尔康药品有限公司 稳定的环孢菌素水性组合物
WO2009142772A2 (en) 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
WO2010047681A1 (en) 2008-10-24 2010-04-29 Bridge Pharma, Inc. Treating xerophthalmia with norketotifen
WO2010059894A1 (en) 2008-11-21 2010-05-27 Bridge Pharma, Inc. Ocular formulations of norketotifen
JP2012520880A (ja) 2009-03-17 2012-09-10 アーシエックス セラピューティックス， インコーポレイテッド ケトチフェンの眼科用製剤および使用方法
JP2012520845A (ja) 2009-03-17 2012-09-10 グラクソ グループ リミテッド Ｉｔｋ阻害剤として使用されるピリミジン誘導体
WO2011068786A2 (en) 2009-12-02 2011-06-09 Bridge Pharma, Inc. Treating xerophthalmia with compounds increasing meibomian gland secretion
TWI500427B (zh) 2010-05-14 2015-09-21 Abbvie Inc Ｉｌ－１結合蛋白
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
SG10201505454SA (en) 2011-07-13 2015-09-29 Abbvie Inc Methods and compositions for treating asthma using anti-il-13 antibodies
WO2014040112A1 (en) 2012-09-17 2014-03-20 Guina Research & Development Pty Ltd Electromagnetic turbine
US8557846B1 (en) 2012-10-23 2013-10-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in dogs
US8778971B2 (en) 2012-10-23 2014-07-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in companion animals
US20150272941A1 (en) 2012-10-30 2015-10-01 Bridge Pharma, Inc. Medicinal treatment of chronic pulmonary inflammatory diseases with norketotifen
US20140120121A1 (en) * 2012-10-30 2014-05-01 Bridge Pharma, Inc. Medicinal treatment of atopic inflammatory diseases
US9347325B2 (en) 2012-10-31 2016-05-24 Solar Turbines Incorporated Damper for a turbine rotor assembly
JP6084473B2 (ja) 2013-02-01 2017-02-22 日立オートモティブシステムズ株式会社 複合センサ
US9345697B2 (en) 2013-08-06 2016-05-24 Bridge Pharma, Inc. Methods of treatment of non-histaminic pruritus
US9138431B2 (en) * 2013-08-06 2015-09-22 Bridge Pharma, Inc. Methods of treatment of histamine H-4 receptor-related pruritus
US9439895B2 (en) 2013-08-06 2016-09-13 Bridge Pharma, Inc. Methods of treating pruritic conditions mediated through non-histaminergic mechanisms in diabetic patients
PL3104853T3 (pl) 2014-02-10 2020-05-18 Respivant Sciences Gmbh Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych
CA2976455C (en) 2015-02-13 2020-09-29 Karcher North America, Inc. Hand held fluid dispensing apparatus
CA2976369A1 (en) 2015-02-13 2016-08-18 Yale University Biaryltriazole inhibitors of macrophage migration inhibitory factor
WO2017035418A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for treatment of immune and inflammatory disorders
US9694003B2 (en) 2015-10-15 2017-07-04 Bridge Pharma, Inc. Formulations and methods for treating high intraocular pressure
MY204310A (en) 2016-09-08 2024-08-22 Emergo Therapeutics Inc Mast cell stabilizers for treatment of hypercytokinemia and viral infection
US11478463B2 (en) 2016-10-18 2022-10-25 Emergo Therapeutics, Inc. Mast cell stabilizers for treatment of chronic inflammatory conditions

Also Published As

Publication number Publication date
US20180066039A1 (en) 2018-03-08
RU2019110150A (ru) 2020-10-08
US20200055926A1 (en) 2020-02-20
MY204310A (en) 2024-08-22
WO2018048989A1 (en) 2018-03-15
AU2023204000A1 (en) 2023-07-13
PH12019500513A1 (en) 2019-05-27
US10501527B2 (en) 2019-12-10
ES2988617T3 (es) 2024-11-21
EP3509596B1 (en) 2024-07-03
BR112019004496A2 (pt) 2019-05-28
CA3036230A1 (en) 2018-03-15
MX2019002781A (es) 2019-09-04
US11072648B2 (en) 2021-07-27
US10494420B2 (en) 2019-12-03
US10160796B2 (en) 2018-12-25
US20180072796A1 (en) 2018-03-15
RU2760682C2 (ru) 2021-11-29
EP3509596A1 (en) 2019-07-17
EP3509596C0 (en) 2024-07-03
CN109952101A (zh) 2019-06-28
KR20190073365A (ko) 2019-06-26
EP3509596A4 (en) 2020-05-06
US20200055927A1 (en) 2020-02-20
US20190085057A1 (en) 2019-03-21
RU2019110150A3 (enExample) 2020-12-18
JP2019529541A (ja) 2019-10-17
MX389999B (es) 2025-03-11
AU2017325010A1 (en) 2019-03-28
US10787502B2 (en) 2020-09-29

Similar Documents

Publication Publication Date Title
IL280459A (en) Phosphoramidates for the treatment of hepatitis b virus
IL272514A (en) Compositions and methods for modifying genomes
IL263972A (en) Dihydropyranopyrimidines for the treatment of viral infections
IL261082A (en) Compositions and methods for modifying genomes
IL259441A (en) Materials and methods for treatment of titin-based myopathies and other titinopaties
PL3554631T3 (pl) Leczenie pacjentów polami ttfields ze zoptymalizowanymi pozycjami elektrod z wykorzystaniem odkształcalnych matryc
DK3597646T3 (da) Terapeutiske forbindelser egnede til den profylaktiske eller terapeutiske behandling af en hiv-virusinfektion
HUE061122T2 (hu) Eljárás hepatitisz B fertõzés kezelésére
EP3360554A4 (en) AGGREGATE AGAINST HEPATITIS B VIRUS
DK3349758T3 (da) Fremgangsmåder til behandling af arenaviridae-virusinfektioner
EP3362028A4 (en) ACTIVE COMPRESSION DECOMPRESSION AND UPPER BODY LIFTING SYSTEM
IL245436A0 (en) New dihydroquinolizinones for the treatment and prevention of hepatitis b virus infection
HRP20190352T1 (hr) Novi 6-kondenzirani heteroarildihidropirimidini za liječenje i profilaksu infekcije virusom hepatitisa b
DK3521282T3 (da) Quinazolinderivater anvendt til behandling af hiv
WO2015153889A3 (en) Materials and methods for the treatment of latent viral infection
HUE053944T2 (hu) 7-Szubsztituált szulfonimidoilpurinon vegyületek vírusfertõzés kezelésére és megelõzésére
DK3043865T3 (da) Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion
IL258259B (en) Adjunctive therapy with 25-hydroxyvitamin d and articles therefor
HUE045906T2 (hu) Új szulfonimidoilpurinon vegyületek és származékok vírusfertõzés kezelésére és megelõzésére
EP3509596C0 (en) NORKETOTIFEN FOR THE TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION
LT3261642T (lt) Chinolino dariniai, skirti naudoti virusinės infekcijos gydymui arba prevencijai
EP3518855A4 (en) PATIENT LIFTING ROBOT
IL249660A0 (en) Methods for treating hepatitis b virus and hepatitis d virus infections
IL292054A (en) Compositions for treatment of abnormal cell growth
LT3137078T (lt) Virusinio hepatito delta infekcijos gydymas